

Allergan's Botox Vista receives marketing authorization in Japan

25 May 2016 | News | By BioSpectrum Bureau

Allergan's Botox Vista receives marketing authorization in Japan



Dublin-headquartered Allergan plc has announced that the Japanese Ministry of Health, Labour and Welfare has approved an additional use for Botox Vista (Allergan's botulinum toxin type A product) as a treatment for crow's feet lines (CFL).

Botox Vista is now indicated for the temporary improvement in the appearance of lateral canthal lines (CFL) in adult patients under the age of 65. This marketing authorization is specific to Allergan's botulinum toxin type A product.

"Our market research has shown that women in Japan have a strong desire to look fresh and revitalized as they age, and they want to do it in a natural way," said Rajkumar Narayanan, Senior Vice President & President of Asia Pacific, Allergan International. "When administered by a trained aesthetic practitioner Botox Vista allows women to achieve the natural-look they want. Achieving this milestone and gaining marketing authorization for CFL in Japan demonstrates Allergan's ongoing commitment to physicians, patients and to our Medical Aesthetics business worldwide."

"CFL are one of the main ageing concerns for many patients around the world, men and women. Whilst these lines form part of our natural eye expression, over time they can become fixed or elongated, even when our faces are relaxed, which can make us look tired or unhappy," said Dr Furuyama Nobutaka, Japan. "By subtly softening the appearance of CFL and glabellar lines combined with BOTOX Vista, we can deliver a refreshed and natural look, helping patients to look like themselves again and improve their self-confidence."